Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
17
07
2020
revised:
03
09
2020
accepted:
03
11
2020
pubmed:
23
11
2020
medline:
16
2
2021
entrez:
22
11
2020
Statut:
ppublish
Résumé
Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear. To study the degree of on-treatment viral antigen decline among patients with pronounced HBV RNA decrease in relation to off-treatment sustained response and HBsAg loss. HBV RNA, HBsAg and hepatitis B core-related antigen (HBcrAg) were quantified in patients with chronic hepatitis B who participated in two randomised controlled trials of peginterferon-based therapy. Sustained response (HBV DNA <2000 IU/mL) and/or HBsAg loss were assessed in patients with and without on-treatment HBV RNA response (either >2 log HBV RNA decline or >1 log decline resulting in an undetectable value at on-treatment week 24), stratified by concomitant HBsAg decline (<0.5/0.5-1/>1 log). We enrolled 279 patients; 176 were hepatitis B e antigen (HBeAg)-positive, and 103 were HBeAg-negative. Sustained response was achieved in 20.4% of patients. At on-treatment week 24, HBV RNA response was associated with higher sustained response rates (27.4% vs 13.0% in non-responders, P = 0.004). However, among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 log HBsAg decline. Among HBV RNA responders, sustained response was achieved in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log decline (n = 12/75, P = 0.001). Similar results were obtained with HBcrAg and when response was defined as HBsAg loss. In this cohort, many patients with HBV RNA response during peginterferon-based treatment did not experience HBsAg and/or HBcrAg decline. The absence of concomitant decline in these viral antigens was associated with low rates of treatment response and HBsAg loss. Future trials should therefore consider kinetics of combined biomarkers to assess anti-viral efficacy. Trial registration, ClinicalTrials.gov: NCT00114361, NCT00146705.
Sections du résumé
BACKGROUND
Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear.
AIM
To study the degree of on-treatment viral antigen decline among patients with pronounced HBV RNA decrease in relation to off-treatment sustained response and HBsAg loss.
METHODS
HBV RNA, HBsAg and hepatitis B core-related antigen (HBcrAg) were quantified in patients with chronic hepatitis B who participated in two randomised controlled trials of peginterferon-based therapy. Sustained response (HBV DNA <2000 IU/mL) and/or HBsAg loss were assessed in patients with and without on-treatment HBV RNA response (either >2 log HBV RNA decline or >1 log decline resulting in an undetectable value at on-treatment week 24), stratified by concomitant HBsAg decline (<0.5/0.5-1/>1 log).
RESULTS
We enrolled 279 patients; 176 were hepatitis B e antigen (HBeAg)-positive, and 103 were HBeAg-negative. Sustained response was achieved in 20.4% of patients. At on-treatment week 24, HBV RNA response was associated with higher sustained response rates (27.4% vs 13.0% in non-responders, P = 0.004). However, among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 log HBsAg decline. Among HBV RNA responders, sustained response was achieved in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log decline (n = 12/75, P = 0.001). Similar results were obtained with HBcrAg and when response was defined as HBsAg loss.
CONCLUSIONS
In this cohort, many patients with HBV RNA response during peginterferon-based treatment did not experience HBsAg and/or HBcrAg decline. The absence of concomitant decline in these viral antigens was associated with low rates of treatment response and HBsAg loss. Future trials should therefore consider kinetics of combined biomarkers to assess anti-viral efficacy. Trial registration, ClinicalTrials.gov: NCT00114361, NCT00146705.
Identifiants
pubmed: 33222190
doi: 10.1111/apt.16172
pmc: PMC7839551
doi:
Substances chimiques
Antigens, Viral
0
Antiviral Agents
0
DNA, Viral
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
RNA
63231-63-0
Banques de données
ClinicalTrials.gov
['NCT00114361', 'NCT00146705']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
314-320Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Hepatology. 2018 Sep;68(3):839-847
pubmed: 29514389
Antiviral Res. 2018 Jan;149:211-220
pubmed: 29183719
Lancet. 2005 Jan 8-14;365(9454):123-9
pubmed: 15639293
J Infect Dis. 2018 Aug 24;218(7):1066-1074
pubmed: 29741634
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):99-100
pubmed: 31711753
Hepatology. 2015 Jan;61(1):66-76
pubmed: 25132147
Hepatol Int. 2019 Jul;13(4):422-430
pubmed: 31172416
N Engl J Med. 2005 Jun 30;352(26):2682-95
pubmed: 15987917
J Infect Dis. 2016 Jan 15;213(2):224-32
pubmed: 26216905
BMC Gastroenterol. 2019 Apr 16;19(1):53
pubmed: 30991954
Gastroenterology. 2020 Jun;158(8):2180-2194
pubmed: 32147484
J Clin Exp Hepatol. 2012 Dec;2(4):353-65
pubmed: 25755457
J Hepatol. 2016 Apr;64(1 Suppl):S41-S48
pubmed: 27084036
Hepatology. 2013 Dec;58(6):1888-96
pubmed: 23744454
Hepatology. 2016 May;63(5):1481-92
pubmed: 27100145
J Hepatol. 2016 Oct;65(4):835-848
pubmed: 27270043
J Viral Hepat. 2018 Sep;25(9):1038-1047
pubmed: 29633430
Gastroenterology. 2019 Apr;156(5):1392-1403.e7
pubmed: 30625297
J Viral Hepat. 2019 Oct;26(10):1156-1163
pubmed: 31135084
J Hepatol. 2017 Feb;66(2):460-462
pubmed: 27826059
J Viral Hepat. 2019 Jul;26(7):786-794
pubmed: 30803126
Liver Int. 2018 Feb;38 Suppl 1:84-89
pubmed: 29427500
J Viral Hepat. 2020 Jun;27(6):610-619
pubmed: 32052503
Antivir Ther. 2015;20(4):369-75
pubmed: 24739420
Hepatology. 2006 Sep;44(3):675-84
pubmed: 16941693
Clin Liver Dis. 2019 Aug;23(3):535-555
pubmed: 31266626
J Viral Hepat. 2020 Mar;27(3):323-328
pubmed: 31667945
Am J Gastroenterol. 2010 Aug;105(8):1762-9
pubmed: 20461068
Clin Infect Dis. 2020 Jan 08;:
pubmed: 31912157
Genes (Basel). 2018 Oct 05;9(10):
pubmed: 30301171
Aliment Pharmacol Ther. 2021 Jan;53(2):314-320
pubmed: 33222190
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166
pubmed: 31711752